Article
Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma.
Cancer medicine - 1 Nov 2022
Kogo Ryunosuke, Manako Tomomi, Iwaya Takeshi, Nishizuka Satoshi, Hiraki Hayato, Sasaki Yasushi, Idogawa Masashi, Tokino Takashi, Koide Ayaka, Komune Noritaka, Yasumatsu Ryuji, Nakagawa Takashi
Abstract excerpt
There is no useful biomarker to evaluate treatment response and early relapse in head and neck squamous cell carcinoma (HNSCC). Circulating tumor DNA (ctDNA) is a promising biomarker for detecting minimal residual diseases and monitoring treatment effect. We investigated whether individualized ctDNA analysis could help monitor treatment response and relapse in HNSCC. Mutation analysis of tumor and peripheral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
